Standard step-wise timelines in the drug discovery process

From: Next Generation Drugs. Source: Authors research & analysis

Created for Global User, Novartis- Global License. IP Address: 160.62.4.10
© Business Insights Limited, 2002
 Basic representation of the current drug discovery path from target
identification and hit-to-lead to development

From: Next Generation Drugs. Source: Authors research & analysis

Created for Global User, Novartis- Global License. IP Address: 160.62.4.10
© Business Insights Limited, 2002
 Information sources to facilitate drug discovery.

From: Next Generation Drugs. Source: Authors research & analysis

Created for Global User, Novartis- Global License. IP Address: 160.62.4.10
© Business Insights Limited, 2002
 Drivers of pharmaceutical innovation

From: Next Generation Drugs. Source: Authors research & analysisIncreasing Competition
Created for Global User, Novartis- Global License. IP Address: 160.62.4.10
© Business Insights Limited, 2002
 The impact of bioinformatics on drug discovery productivity

From: Next Generation Drugs. Source: Authors research & analysis, Datamonitor
Created for Global User, Novartis- Global License. IP Address: 160.62.4.10
© Business Insights Limited, 2002
 Key enabling technologies driving pharmaceutical innovation

From: Next Generation Drugs. Source: Authors research & analysis

Created for Global User, Novartis- Global License. IP Address: 160.62.4.10
© Business Insights Limited, 2002
 Genetic data generated by the Human Genome Project

From: Next Generation Drugs. Source: Authors research & analysis

Created for Global User, Novartis- Global License. IP Address: 160.62.4.10
© Business Insights Limited, 2002
 Genomics product technologies: turning genomics data into drugs

From: Next Generation Drugs. Source: Authors research & analysis

Created for Global User, Novartis- Global License. IP Address: 160.62.4.10
© Business Insights Limited, 2002
 New protein technologies: Driving the proteomics industry

From: Next Generation Drugs. Source: Authors research & analysis

Created for Global User, Novartis- Global License. IP Address: 160.62.4.10
© Business Insights Limited, 2002
 Pharmacogenomics: use in clinical trials and impact on the stop-go
decision

From: Next Generation Drugs. Source: Authors research & analysis, Datamonitor
Created for Global User, Novartis- Global License. IP Address: 160.62.4.10
© Business Insights Limited, 2002
 Drug-response genes

From: Next Generation Drugs. Source: Authors research & analysis

Created for Global User, Novartis- Global License. IP Address: 160.62.4.10
© Business Insights Limited, 2002
 Resource allocation in the research and development process

From: Next Generation Drugs. Source: Authors research & analysis, Datamonitor
Created for Global User, Novartis- Global License. IP Address: 160.62.4.10
© Business Insights Limited, 2002
 Genomics-driven companies with respective technology platforms

From: Next Generation Drugs. Source: Authors research & analysis

Created for Global User, Novartis- Global License. IP Address: 160.62.4.10
© Business Insights Limited, 2002
 Opportunities for generating revenues from genomics

From: Next Generation Drugs. Source: Authors research & analysis

Created for Global User, Novartis- Global License. IP Address: 160.62.4.10
© Business Insights Limited, 2002
 The impact of drug discovery technologies on reducing development
time

From: Next Generation Drugs. Source: Authors research & analysis, Datamonitor
Created for Global User, Novartis- Global License. IP Address: 160.62.4.10
© Business Insights Limited, 2002
 Importance of key enabling technologies, 1999-2005

From: Next Generation Drugs. Source: Authors research & analysis, Datamonitor
Created for Global User, Novartis- Global License. IP Address: 160.62.4.10
© Business Insights Limited, 2002
 Change in perceived relative importance of drug discovery
technologies, 1999-2005

From: Next Generation Drugs. Source: Authors research & analysis, Datamonitor
Created for Global User, Novartis- Global License. IP Address: 160.62.4.10
© Business Insights Limited, 2002
 Companies using pharmacogenomic studies in drug development

From: Next Generation Drugs. Source: Reuters Business Insight Pharmacogenomics Survey, 2000
Created for Global User, Novartis- Global License. IP Address: 160.62.4.10
© Business Insights Limited, 2002
 Benefits of genetic profiling in R&D

From: Next Generation Drugs. Source: Authors research & analysis

Created for Global User, Novartis- Global License. IP Address: 160.62.4.10
© Business Insights Limited, 2002